<DOC>
	<DOCNO>NCT00234429</DOCNO>
	<brief_summary>The primary objective study compare activity raltitrexed ZD1839 versus raltitrexed alone second line chemotherapy subject colorectal carcinoma estimate progression free survival ( PFS ) treatment arm .</brief_summary>
	<brief_title>A Phase 2 Study Tomudex &amp; Iressa Second Line Chemotherapy Subjects With Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>Male female , age 18 75 year , inclusive histologicallyconfirmed metastatic colorectal carcinoma ; measurable lesion accord Response Evaluation Criteria Solid Tumours ( RECIST ) relapse treatment fluoropyrimidinebased chemotherapy prior chemotherapeutic regimen metastatic locally advanced disease interval least 4 week last administration chemotherapy first administration study treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 life expectancy least 12 week Known severe hypersensitivity raltitrexed excipients product know severe hypersensitivity raltitrexed excipients product active infection uncontrolled diarrhoea cerebral metastasis meningeal carcinomatosis evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude ) simultaneous antitumoral treatment radiotherapy within 2 week entry study coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ unresolved chronic toxicity great common toxicity criterion ( CTC ) grade 2 previous anticancer therapy ( except alopecia ) significant clinical disorder laboratory finding ( leukocyte count le 3.0 x 109 /litre ( L ) platelets less 100 x 109 /L ; serum total bilirubin 2.0 mg/dl ; judge investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic , renal disease ) ; creatinine clearance â‰¥ 65ml/min ( accord CockcroftGault formula ) ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2 time upper limit reference range ( ULRR ) demonstrable liver metastasis , great 5 time ULRR presence liver metastasis ) pregnancy breast feeding ( woman childbearing potential ) concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , ST John 's Wort ; Treatment non approve investigational drug within 30 day Day 1 study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Colorectal carcinoma advance disease</keyword>
</DOC>